

# Mauro Novelli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7354936/publications.pdf>

Version: 2024-02-01

15  
papers

371  
citations

1040056

9  
h-index

1125743

13  
g-index

15  
all docs

15  
docs citations

15  
times ranked

485  
citing authors

#	ARTICLE	IF	CITATIONS
1	CD38 Expression by Circulating and Skin-Infiltrating Lymphocytes from Sezary Syndrome Patients: A Flow Cytometry and Immunohistochemistry Study. <i>Disease Markers</i> , 2022, 2022, 1-7.	1.3	2
2	Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or S�azary Syndrome. <i>Journal of Investigative Dermatology</i> , 2021, 141, 484-495.	0.7	31
3	Infections in S�azary syndrome: A retrospective cohort study of 113 patients. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	1.2	2
4	HERV-E expression in peripheral mononuclear cells of patients with psoriasis. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, 42-45.	0.2	1
5	Is HERV-K and HERV-W expression regulated by mir-155 in S�azary Syndrome?. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 477-482.	0.8	1
6	BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti�PD-1 Antibody. <i>Clinical Cancer Research</i> , 2018, 24, 3377-3385.	7.0	31
7	DNA from Human Polyomaviruses, MWPvV, HPyV6, HPyV7, HPyV9 and HPyV12 in Cutaneous T-cell Lymphomas. <i>Anticancer Research</i> , 2018, 38, 4111-4114.	1.1	9
8	Co-isolation and analysis of extracellular vesicle (EV)-associated DNA and cell free DNA (cfDNA) to improve the diagnostic and prognostic value of circulating BRAF V600E in metastatic melanoma patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21564-e21564.	1.6	0
9	Erythema multiforme�like lesions in primary cutaneous aggressive cytotoxic epidermotropic <sc>CD8</sc>+ T�cell lymphoma: A diagnostic and therapeutic challenge. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 867-873.	1.3	11
10	Melanoma of the lower extremities: foot site is an independent risk factor for clinical outcome. <i>International Journal of Dermatology</i> , 2015, 54, 1023-1029.	1.0	13
11	Spiky follicular mycosis fungoides: a clinicopathologic study of 8 cases. <i>Journal of Cutaneous Pathology</i> , 2015, 42, 164-172.	1.3	27
12	Blood Flow Cytometry in S�azary Syndrome. <i>American Journal of Clinical Pathology</i> , 2015, 143, 57-69.	0.7	45
13	The inclusion complex of 4-hydroxynonenal with a polymeric derivative of �2-cyclodextrin enhances the antitumoral efficacy of the aldehyde in several tumor cell lines and in a three-dimensional human melanoma model. <i>Free Radical Biology and Medicine</i> , 2013, 65, 765-777.	2.9	14
14	Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients. <i>Haematologica</i> , 2007, 92, 784-794.	3.5	172
15	CD26 Expression on Cutaneous Infiltrates from Patients with Cutaneous T-Cell Lymphoma (CTCL). , 2003, 524, 223-234.		12